Pyrukynd Tablet, Film Coated
FDA Label NDC 71334-215

33 label sections · Submitted to the FDA by Agios Pharmaceuticals, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Agios Pharmaceuticals, Inc. for the product Pyrukynd (NDC 71334-215). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1 indications and usage, 2.1 recommended dose, 2.2 missed dose, 2.3 interruption or discontinuation, 2.4 recommended dosage for drug interactions, 2.5 dose modifications for adverse reactions and hemoglobin levels above normal, 3 dosage forms and strengths, 4 contraindications, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

* Please review the disclaimer below.